Drug Trials Snapshots: MYQORZO

Why It Matters

The drug offers the first disease‑modifying oral therapy for oHCM, potentially reducing symptom burden and improving exercise capacity, while its safety profile and REMS requirement highlight the need for careful patient monitoring.

Key Takeaways

• FDA approved MYQORZO for symptomatic oHCM
• Trial showed 1.7 mL/min/kg pVO₂ increase
• Benefit consistent across sex, age, race subgroups
• Hypertension occurred in 8% vs 2% placebo
• REMS program required due to heart failure risk

Pulse Analysis

The therapeutic arena for obstructive hypertrophic cardiomyopathy has long been dominated by symptom‑relief agents such as beta‑blockers, calcium‑channel blockers, and invasive septal reduction procedures. Oral myosin inhibition represents a novel mechanism that directly targets the hypercontractile state of the myocardium. MYQORZO (aficamten) received FDA approval on December 19 2025, becoming the first approved oral myosin inhibitor for adult patients with symptomatic oHCM. Its entry addresses a sizable unmet need, offering clinicians a pharmacologic option that could delay or replace more invasive interventions. The drug’s pharmacokinetic profile supports once‑daily dosing, simplifying adherence.

The pivotal SEQUOIA‑HCM trial enrolled 282 participants from 82 sites in 14 countries, randomizing them 1:1 to MYQORZO or placebo for 24 weeks. The primary endpoint—change in peak oxygen uptake (pVO₂)—improved by a least‑squares mean of 1.7 mL/min/kg versus no change on placebo, a statistically robust result (p < 0.0001). Subgroup analyses revealed comparable gains across males and females, patients under and over 65, and both White and Asian cohorts, suggesting the drug’s efficacy is broadly applicable despite the limited representation of Black participants. The ANCOVA model adjusted for baseline pVO₂ and site variability, strengthening confidence in the observed treatment effect.

Safety considerations temper the enthusiasm. Hypertension emerged in 8% of treated patients compared with 2% on placebo, and a serious heart‑failure signal triggered a mandatory REMS program to control distribution and monitor drug interactions. These precautions underscore the importance of patient selection and vigilant follow‑up. From a market perspective, MYQORZO’s oral route and disease‑modifying claim position it to capture a substantial share of the oHCM space, potentially reshaping treatment algorithms and prompting further research into myosin inhibition for other cardiomyopathies. Long‑term registries will be essential to quantify real‑world outcomes and refine risk‑mitigation strategies.